TELIX Pharmaceuticals Ltd Cash Flow Conversion Efficiency

Latest as of June 2025: 0.066x

TELIX Pharmaceuticals Ltd cash flow conversion efficiency. Based on the latest financial reports, TELIX Pharmaceuticals Ltd (TLX) has a cash flow conversion efficiency ratio of 0.066x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$27.98 Million ≈ $19.80 Million USD) by net assets (AU$421.94 Million ≈ $298.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is TELIX Pharmaceuticals Ltd worth for the company's overall valuation and market capitalisation.

Cash Flow Conversion Efficiency of TELIX Pharmaceuticals Ltd (2017–2024)

Cash flow conversion efficiency of TELIX Pharmaceuticals Ltd from 2017 to 2024. This chart illustrates how TELIX Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for TELIX Pharmaceuticals Ltd for real-time trading data and today's change.

TELIX Pharmaceuticals Ltd Cash Flow Conversion Ratio Explained

TELIX Pharmaceuticals Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

TELIX Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of TELIX Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Review TLX free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Company	Cash Flow Conversion Efficiency
Xinhu Zhongbao Co Ltd SHG:600208	0.011x
Sinomach Heavy Equipment Group Co Ltd SHG:601399	-0.020x
SEB SA PA:SK	0.051x
JA Solar Technology Co Ltd SHE:002459	0.010x
Galaxy Digital Holdings Ltd NASDAQ:GLXY	0.012x
ICU Medical Inc NASDAQ:ICUI	0.029x
TISCO Financial Group Public Company Limited BK:TISCO	0.075x
Avista Corporation NYSE:AVA	0.064x

Annual Cash Flow Conversion Efficiency for TELIX Pharmaceuticals Ltd (2017–2024)

The table below shows the annual cash flow conversion efficiency of TELIX Pharmaceuticals Ltd from 2017 to 2024. Also see TELIX Pharmaceuticals Ltd (TLX) total assets for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	AU$568.21 Million ≈ $402.05 Million	AU$43.03 Million ≈ $30.45 Million	0.076x	-52.79%
2023-12-31	AU$148.91 Million ≈ $105.36 Million	AU$23.88 Million ≈ $16.90 Million	0.160x	+119.29%
2022-12-31	AU$76.92 Million ≈ $54.42 Million	AU$-63.97 Million ≈ $-45.26 Million	-0.832x	+94.89%
2021-12-31	AU$3.64 Million ≈ $2.58 Million	AU$-59.33 Million ≈ $-41.98 Million	-16.290x	-65771.77%
2020-12-31	AU$79.02 Million ≈ $55.91 Million	AU$1.96 Million ≈ $1.39 Million	0.025x	+107.52%
2019-12-31	AU$70.73 Million ≈ $50.05 Million	AU$-23.33 Million ≈ $-16.51 Million	-0.330x	+15.88%
2018-12-31	AU$52.90 Million ≈ $37.43 Million	AU$-20.75 Million ≈ $-14.68 Million	-0.392x	-220.50%
2017-12-31	AU$49.29 Million ≈ $34.88 Million	AU$-6.03 Million ≈ $-4.27 Million	-0.122x	--

About TELIX Pharmaceuticals Ltd

AU:TLX Australia Biotechnology

Market Cap

$3.11 Billion

AU$4.39 Billion AUD

Market Cap Rank

#4633 Global

#118 in Australia

Share Price

AU$13.13

Change (1 day)

-2.60%

52-Week Range

AU$8.63 - AU$17.85

All Time High

AU$31.14